BioLife Solutions (BLFS) 10-Q 9 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 06, 2019
Document Information [Line Items]
Entity Registrant Name	BIOLIFE SOLUTIONS INC
Entity Central Index Key	0000834365
Trading Symbol	blfs
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		19,002,764
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 19,617	$ 30,657
Accounts receivable, trade, net of allowance for doubtful accounts of $26 and $0 at June 30, 2019 and December 31, 2018, respectively	3,832	3,045
Inventories	5,306	3,509
Prepaid expenses and other current assets	384	353
Total current assets	29,139	37,564
Property and equipment
Leasehold improvements	1,284	1,284
Furniture and computer equipment	577	706
Manufacturing and other equipment	1,733	1,657
Subtotal	3,594	3,647
Less: Accumulated depreciation	(2,276)	(2,328)
Net property and equipment	1,318	1,319
Operating lease right-of-use assets	1,079
Investment in SAVSU	6,100	6,548
Intangible assets, net	4,446
Goodwill	9,524
Long-term deposits	136	36
Total assets	51,742	45,467
Current liabilities
Accounts payable	876	720
Accrued expenses and other current liabilities	204	91
Accrued compensation	963	998
Lease liability - operating, current portion	665
Lease liability – financing, current portion	14
Deferred rent, current portion		130
Contingent consideration - current	371
Total current liabilities	3,093	1,939
Deferred rent, long-term		349
Long-term lease liability - operating	806
Long-term lease liability - financing	10
Other long-term liabilities	7	31
Contingent consideration – long-term	1,560
Total liabilities	5,476	2,319
Commitments and Contingencies (Note 10)
Shareholders’ equity
Common stock, $0.001 par value; 150,000,000 shares authorized, 18,898,609 and 18,547,406 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	19	19
Additional paid-in capital	116,013	114,160
Accumulated deficit	(69,766)	(71,031)
Total shareholders’ equity	46,266	43,148
Total liabilities and shareholders’ equity	$ 51,742	$ 45,467

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accounts receivable, allowance for doubtful accounts	$ 26	$ 0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	18,898,609	18,547,406
Common stock, outstanding (in shares)	18,898,609	18,547,406

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Product sales	$ 6,701	$ 5,178	$ 12,471	$ 8,993
Cost of product sales	1,958	1,537	3,606	2,901
Gross profit	4,743	3,641	8,865	6,092
Operating expenses
Research and development	739	325	1,111	671
Sales and marketing	928	641	1,776	1,253
General and administrative	2,118	1,390	4,321	2,744
Acquisition costs	39		247
Total operating expenses	3,824	2,356	7,455	4,668
Operating income	919	1,285	1,410	1,424
Other income (expenses), net
Interest income	137	32	307	41
Interest expense	(1)	(1)	(4)	(1)
Loss from equity-method investment in SAVSU	(217)	(177)	(448)	(321)
Total other income (expenses), net	(81)	(146)	(145)	(281)
Income before provision for income taxes	838	1,139	1,265	1,143
Income taxes
Net income	838	1,139	1,265	1,143
Less: Preferred stock dividends		(93)		(200)
Net income attributable to common stockholders	$ 838	$ 1,046	$ 1,265	$ 943
Basic net income per common share (in dollars per share)	$ 0.04	$ 0.07	$ 0.07	$ 0.06
Diluted net income per common share (in dollars per share)	$ 0.03	$ 0.05	$ 0.05	$ 0.05
Basic shares used to compute earnings per share (in shares)	18,819,459	15,180,169	18,734,401	14,642,378
Diluted shares used to compute earnings per share (in shares)	24,539,299	20,374,358	24,439,959	19,063,595

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	4,250	14,021,422
Balance at Dec. 31, 2017		$ 14	$ 84,036	$ (73,958)	$ 10,092
Stock based compensation			748		748
Stock option/warrant exercises (in shares)		2,003,605
Stock option/warrant exercises		$ 2	8,897		8,899
Stock issued – on vested RSUs (in shares)		76,539
Stock issued – on vested RSUs
Net income				1,143	1,143
Series A preferred stock redemption (in shares)	(1,063)
Series A preferred stock redemption			(1,063)		(1,063)
Stock issued for services (in shares)		5,939
Stock issued for services			36		36
Preferred stock dividends				(200)	(200)
Balance (in shares) at Jun. 30, 2018	3,187	16,107,505
Balance at Jun. 30, 2018		$ 16	92,654	(73,015)	19,655
Balance (in shares) at Mar. 31, 2018	4,250	14,145,413
Balance at Mar. 31, 2018		$ 14	84,518	(74,061)	10,471
Stock based compensation			374		374
Stock option/warrant exercises (in shares)		1,941,167
Stock option/warrant exercises		$ 2	8,825		8,827
Stock issued – on vested RSUs (in shares)		20,925
Stock issued – on vested RSUs
Net income				1,139	1,139
Series A preferred stock redemption (in shares)	(1,063)
Series A preferred stock redemption			(1,063)		(1,063)
Preferred stock dividends				(93)	(93)
Balance (in shares) at Jun. 30, 2018	3,187	16,107,505
Balance at Jun. 30, 2018		$ 16	92,654	(73,015)	19,655
Balance (in shares) at Dec. 31, 2018		18,547,406
Balance at Dec. 31, 2018		$ 19	114,160	(71,031)	43,148
Stock based compensation			1,252		1,252
Stock option/warrant exercises (in shares)		265,061
Stock option/warrant exercises			601		601
Stock issued – on vested RSUs (in shares)		86,142
Stock issued – on vested RSUs
Net income				1,265	1,265
Balance (in shares) at Jun. 30, 2019		18,898,609
Balance at Jun. 30, 2019		$ 19	116,013	(69,766)	46,266
Balance (in shares) at Mar. 31, 2019		18,717,095
Balance at Mar. 31, 2019		$ 19	114,951	(70,604)	44,366
Stock based compensation			646		646
Stock option/warrant exercises (in shares)		160,364
Stock option/warrant exercises			416		416
Stock issued – on vested RSUs (in shares)		21,150
Stock issued – on vested RSUs
Net income				838	838
Balance (in shares) at Jun. 30, 2019		18,898,609
Balance at Jun. 30, 2019		$ 19	$ 116,013	$ (69,766)	$ 46,266

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities
Net income	$ 1,265,000	$ 1,143,000
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	209,000	161,000
Stock-based compensation expense	1,252,000	748,000
Amortization of deferred rent related to lease incentives	0	(63,000)
Amortization of operating lease liability	(87,000)
Interest expense – finance type lease	2,000
Loss from equity-method investment in SAVSU	448,000	321,000
Amortization of intangible assets	104,000
Change in operating assets and liabilities
Accounts receivable, trade	(632,000)	(1,145,000)
Inventories	(1,341,000)	(275,000)
Prepaid expenses and other current assets	(32,000)	(103,000)
Accounts payable	(36,000)	168,000
Accrued compensation and other current liabilities	(20,000)	4,000
Deferred rent		(6,000)
Other liabilities	(53,000)
Net cash provided by operating activities	1,079,000	953,000
Cash flows from investing activities
Payments related to the Astero Bio Acquisition, net of cash acquired	(12,438,000)
Investment in equity investment SAVSU		(1,000,000)
Purchase of property and equipment	(267,000)	(61,000)
Net cash used in investing activities	(12,705,000)	(1,061,000)
Cash flows from financing activities
Payments on equipment loan	(8,000)	(5,000)
Payments on capital lease obligations	(7,000)	(7,000)
Proceeds from exercise of common stock options and warrants	601,000	8,899,000
Payments of preferred stock dividends		(213,000)
Payments for redemption of preferred stock		(1,063,000)
Net cash provided by financing activities	586,000	7,611,000
Net increase (decrease) in cash and cash equivalents	(11,040,000)	7,503,000
Cash and cash equivalents - beginning of period	30,657,000	6,663,000
Cash and cash equivalents - end of period	19,617,000	14,166,000
Non-cash investing and financing activities
Series A preferred stock dividends accrued not yet paid		93,000
Stock issued for services provided in prior period included in liabilities at year-end		36,000
Receivables converted to equity investment in SAVSU		150,000
Purchase of equipment with debt		18,000
Purchase of property and equipment not yet paid	$ 4,000	$ 20,000

Note 1 - Organization and Signi

Note 1 - Organization and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Organization and Significant Accounting Policies Business BioLife Solutions, Inc. (“BioLife,” “us,” “we,” “our,” or the “Company”) is a leading developer, manufacturer and supplier of a portfolio of bioproduction tools including; proprietary biopreservation media and automated thawing devices for cell and gene therapies. Our CryoStor ® ® ® Basis of Presentation We have prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full year. These consolidated financial statements and accompanying notes should be read in conjunction with the financial statements and notes thereto in our Annual Report on Form 10 -K for the year ended December 31, 2018 on file with the SEC. Changes in Significant Accounting Policies The following significant accounting policies have been added or updated since our Annual Report on Form 10 -K for the year ended December 31, 2018. Business Combinations The Company’s identifiable assets acquired and liabilities assumed in a business combination are recorded at their acquisition date fair values. The valuation requires management to make significant estimates and assumptions, especially with respect to long-lived and intangible assets. Critical estimates in valuing intangible assets include, but are not limited to: ● future expected cash flows, including revenue and expense projections; ● discount rates to determine the present value of recognized assets and liabilities and; ● revenue volatility to determine contingent consideration using option pricing models The Company’s estimates of fair value are based upon assumptions it believes to be reasonable, but that are inherently uncertain and unpredictable. Assumptions may be incomplete or inaccurate, and unanticipated events and circumstances may occur. Goodwill is calculated as the excess of the purchase price over the fair value of net assets acquired, including the amount assigned to identifiable intangible assets. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which these costs are incurred. The results of operations of an acquired business are included in the consolidated financial statements beginning at the acquisition date. The Company estimates the acquisition date fair value of the acquisition-related contingent consideration using various valuation approaches, including option pricing models, as well as significant unobservable inputs, reflecting the Company’s assessment of the assumptions market participants would use to value these liabilities. The fair value of the contingent consideration is remeasured each reporting period, with any change in the value recorded as other income or expense. During the measurement period, which may be up to one year from the acquisition date, any refinements made to the fair value of the assets acquired, liabilities assumed, or contingent consideration are recorded in the period in which the adjustments are recognized. Upon the conclusion of the measurement period or final determination of the fair value of the assets acquired, liabilities assumed, or contingent consideration, whichever comes first, any subsequent adjustments are recognized in the consolidated statements of operations. Goodwill Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. Goodwill is not amortized but is tested for impairment at least annually. The Company reviews goodwill for impairment annually at the end of its fourth fiscal quarter and whenever events or changes in circumstances indicate that the fair value of a reporting unit may be less than its carrying amount (a triggering event). The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the quantitative goodwill impairment test described in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350. The more likely than not threshold is defined as having a likelihood of more than 50 percent. If, after assessing the totality of events or circumstances, the Company determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the quantitative goodwill impairment test is unnecessary and goodwill is considered to be unimpaired. However, if based on the qualitative assessment the Company concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company will proceed with performing the quantitative goodwill impairment test. In performing the quantitative goodwill impairment test, the Company determines the fair value of each reporting unit and compares it to its carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets assigned to that unit, goodwill is not impaired. If the carrying value of a reporting unit exceeds its fair value, the Company records an impairment loss equal to the difference. As of June 30, 2019, management believes there are no indications of impairment. Intangible Assets Intangible assets consist of developed technology, customer relationships, and tradenames and trademarks, resulting from the Company’s acquisitions. Intangible assets are recorded at fair value on the date of acquisition and amortized over their estimated useful lives on a straight-line basis. Significant Accounting Policies Update In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016 - 02, Leases: Topic 842 (“ASU 2016 - 02” ) that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. Under the new guidance, leases will continue to be classified as either finance or operating, with classification affecting the pattern of expense recognition in the Statements of Operations. Lessor accounting is largely unchanged under ASU 2016 - 02. We adopted ASU 2016 - 02 and related ASUs (collectively ASC 842 ) effective January 1, 2019 using the additional transition option for the modified retrospective method and did not restate comparative periods. Consequently, periods before January 1, 2019 will continue to be reported in accordance with the prior accounting guidance, ASC 840, Leases. We elected the package of practical expedients, which permits us to retain prior conclusions about lease identification, lease classification and initial direct costs for leases that commenced before January 1, 2019. The new standard also provides practical expedients for an entity’s ongoing accounting. We elected the short-term lease recognition exemption for all leases that qualify. We also elected the practical expedient to combine lease and non-lease components for all of our leases other than net lease real estate leases. The adoption of this standard resulted in the recording of operating lease right-of-use assets of $1.3 million and short-term and long-term lease liabilities of $1.8 million as of January 1, 2019. The difference between right-of-use assets and lease liabilities relates to liabilities of $0.5 million for deferred rent and lease incentives liabilities that were included on our Balance Sheet prior to adoption of ASC 842. These amounts were eliminated at the time of adoption and are included in the lease liabilities. Adoption of ASC 842 did not have a material impact on the Company’s net earnings and had no impact on cash flows. Principles of Consolidation The consolidated financial statements for the three and six months ended June 30, 2019 include the accounts of the Company and as of April 1, 2019, its wholly-owned subsidiary, Astero Bio Corporation. All intercompany balances and transactions have been eliminated in consolidation. The acquisition of Astero closed on April 1, 2019 and thus the financial statements for the three and six months ended June 30, 2018 and the balance sheet as of December 31, 2018, only include accounts of the Company. Equity Method Investments We account for our ownership in SAVSU Technologies, Inc. (“SAVSU”) using the equity method of accounting. This method states that if the investment provides us the ability to exercise significant influence, but not control, over the investee, we account for the investment under the equity method. Significant influence is generally deemed to exist if the Company’s ownership interest in the voting stock of the investee ranges between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment is recorded at its initial carrying value in the consolidated balance sheet and is periodically adjusted for capital contributions, dividends received and our share of the investee’s earnings or losses together with other-than-temporary impairments which are recorded as a component of other income (expense), net in the consolidated statements of operations. For the three and six months ended June 30, 2019, SAVSU’s net loss totaled $0.5 million and $1.0 million, respectively which our ownership resulted in a $0.2 million and $0.4 million loss, respectively. For the three and six months ended June 30, 2018, SAVSU’s net loss totaled $0.6 million and $1.1 million, respectively, of which our ownership resulted in a $0.2 million and $0.3 million loss, respectively. Concentrations of credit risk and business risk In the three months ended June 30, 2019, we derived approximately 17% of our product revenue from one customer and in the six months ended June 30, 2019, we derived approximately 20% of our revenue from one customer. In the three months ended June 30, 2018, we derived approximately 38% of our product revenue from three customers and in the six months ended June 30, 2018, we derived approximately 27% of our revenue from two customers. No other customer accounted for more than 10% of revenue in the three and six months ended June 30, 2019 or 2018. In the three months ended June 30, 2019 and 2018, we derived approximately 82% and 87%, of our revenue from CryoStor products, respectively. In each of the six months ended June 30, 2019 and 2018, we derived approximately 86%, of our revenue from CryoStor products. At June 30, 2019, two customers accounted for approximately 28% of total gross accounts receivable. At December 31, 2018, three customers accounted for approximately 71% of total gross accounts receivable. Revenue from customers located in Canada represented 17% and 20% and in all other foreign countries represented 12% and 14% of total revenue during the three and six months ended June 30, 2019, respectively. Revenue from customers located in Canada represented 11% and 12% and in all other foreign countries represented 11% and 11% of total revenue during the three and six months ended June 30, 2018, respectively. All revenue from foreign customers is denominated in United States dollars. Recent Accounting Pronouncements There have been no new accounting pronouncements not yet effective that have significance, or potential significance, to our Financial Statements.

Note 2 - Fair Value Measurement

Note 2 - Fair Value Measurement	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	2. Fair Value Measurement In accordance with FASB ASC Topic 820, 820” 820 820 three Level 1 Level 2 1 not Level 3 As of June 30, 2019 December 31, 2018, not The following tables set forth the Company’s financial assets measured at fair value on a recurring basis as of June 30, 2019 December 31, 2018, three As of June 30, 2019 Level 1 Level 2 Level 3 Total Assets: Total cash and cash equivalents $ 19,617 $ — $ — $ 19,617 Liabilities: Contingent consideration - business combinations $ — $ — $ 1,931 $ 1,931 As of December 31, 2018 Level 1 Level 2 Total Total cash and cash equivalents $ 30,657 $ — $ 30,657 The fair values of cash and cash equivalents classified as Level 1 3 3. no June 30, 2019, three six June 30, 2019. no 2 3 not 1 2 six June 30, 2019 twelve December 31, 2018.

Note 3 - Acquisition of Astero

Note 3 - Acquisition of Astero Bio Corporation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Business Combination Disclosure [Text Block]	3. Acquisition of Astero Bio Corporation On April 1, 2019, Astero’s ThawSTAR product line is comprised of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The products improve the quality of administration of high-value, temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Consideration transferred The Astero Acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, $12.5 $8.5 three $1.9 $324,000, $4.6 $9.5 not may Total consideration recorded for the acquisition of Astero is as follows (amounts in thousands): Cash consideration $ 12,521 Contingent consideration 1,931 Working capital adjustment (71 ) Total consideration transferred $ 14,381 Transaction costs related to the acquisition are expensed as incurred and are not $39,000 $247,000 three six June 30, 2019, Fair Value of Net Assets Acquired The table below represents the purchase price allocation to the net assets acquired based on their estimated fair values (amounts in thousands). We may one March 31, 2019. Cash and cash equivalents $ 12 Accounts receivable 154 Inventory 456 Customer relationships 160 Tradenames 470 Developed technology 3,920 Goodwill 9,524 Other assets 100 Accounts Payable (251 ) Other liabilities (164 ) Fair value of net assets acquired $ 14,381 The fair value of Astero’s identifiable intangible assets and estimated useful lives have been preliminary estimated as follows (amounts in thousands): Estimated Fair Value Estimated Useful Life (Years) Customer relationships $ 160 4 Tradenames 470 9 Developed technologies 3,920 5 – 9 Total identifiable intangible assets $ 4,550 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three third Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Acquired Goodwill The goodwill of $9.5 not Revenue, Net Income and Pro Forma Presentation The Company recorded revenue from Astero of $374,000 $542,000 three six June 30, 2019. April 1, 2019 January 1, 2018 six June 30, 2019 2018 $104,000 $208,000 $4.6 $108,000 $216,000, $47,000 $94,000, $247,000 $103,000 six June 30, 2019. not not January 1, 2018 Six Months Ended June 30, (In thousands) 2019 2018 Total revenue $ 12,681 $ 9,016 Net income attributable to common stockholders $ 801 $ 258 Earnings per share: Basic $ 0.04 $ 0.02 Diluted $ 0.03 $ 0.01

Note 4 - Inventory

Note 4 - Inventory	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventory Inventory consists of the following at June 30, 2019 December 31, 2018: (In thousands) June 30, 2019 December 31, 2018 Raw materials $ 2,068 $ 1,453 Work in progress 275 652 Finished goods 2,963 1,404 Total $ 5,306 $ 3,509

Note 5 - Deferred Rent

Note 5 - Deferred Rent	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Deferred Rent [Text Block]	5. Deferred Rent Deferred rent consists of the following at December 31, 2018. January 1, 2019 2016 02 12 (In thousands) December 31, 2018 Landlord-funded leasehold improvements $ 1,125 Less accumulated amortization (757 ) Total 368 Straight line rent adjustment 111 Total deferred rent $ 479 During the three six June 30, 2019, no three six June 30, 2018, $32,000 $63,000, Straight line rent adjustment for the three six June 30, 2018

Note 6 - Share-based Compensati

Note 6 - Share-based Compensation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	6. Share-based Compensation Service Vesting-Based Stock Options The following is a summary of service vesting-based stock option activity for the six June 30, 2019 June 30, 2019: Six Month Period Ended June 30, 2019 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 2,043,402 $ 1.91 Granted — $ — Exercised (236,061 ) $ 1.96 Forfeited (3,438 ) $ 5.69 Expired — $ — Outstanding service vesting-based at June 30, 2019 1,803,903 $ 1.90 Service vesting-based options exercisable at June 30, 2019 1,600,799 $ 1.87 We recognized stock compensation expense related to service vesting-based options of $95,000 $149,000 three June 30, 2019 2018, $240,000 $303,000 six June 30, 2019 June 30, 2018, June 30, 2019, $27.2 $24.1 June 30, 2019. three June 30, 2019 2018 $2.0 $724,000, six June 30, 2019 2018 $3.5 $1.0 no six June 30, 2019 2018. June 30, 2019, 5.2 5.1 June 30, 2019 $279,000 1.4 Performance-based Stock Options The Company’s Board of Directors implemented a Management Performance Bonus Plan for 2017. December 31, 2017, 1,000,000 $1.64, 2017 50% 2017, 50% one not no February 27, 2018, 2017 999,997 50% March 8, 2018 50% March 8, 2019. The following is a summary of performance-based stock option activity for the six June 30, 2019, June 30, 2019: Six Month Period Ended June 30, 2019 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 964,997 $ 1.64 Granted — $ — Exercised — $ — Outstanding performance-based at June 30, 2019 964,997 $ 1.64 Performance-based options exercisable at June 30, 2019 964,997 $ 1.64 We recognized stock compensation expense related to performance-based options of none $127,000 three June 30, 2019 2018, none $252,000 six June 30, 2019 2018. June 30, 2019, $14.8 June 30, 2019. three six June 30, 2019 none three six June 30, 2018 $285,000. June 30, 2019, 2.5 June 30, 2019 There were no three six June 30, 2019 2018. Restricted Stock Service vesting-based restricted stock The following is a summary of service vesting-based restricted stock activity for the six June 30, 2019, June 30, 2019: Six Month Period Ended June 30, 2019 Service vesting-based restricted stock Number of Grant-Date Outstanding at beginning of year 279,919 $ 5.00 Granted 177,718 $ 17.80 Vested (86,142 ) $ 4.51 Forfeited (21,269 ) $ 10.17 Outstanding at June 30, 2019 350,226 $ 11.30 The aggregate fair value of the service vesting-based awards granted during the three June 30, 2019 2018 $548,000 $154,000, six June 30, 2019 2018 $3.2 $1.1 three June 30, 2019 2018 $369,000 $174,000, six June 30, 2019 2018 $1.2 $481,000, We recognized stock compensation expense of $268,000 $98,000 three June 30, 2019 2018, $522,000 $193,000 six June 30, 2019 2018, June 30, 2019, $3.6 3.4 Performance-based restricted stock In 2019, 94,247 four 94,247 0% 200% January 1, 2019 December 31, 2020 20 94,247 50th may 188,494 80th no 30th 29,604 April 1, 2019 two Six Month Period Ended June 30, 2019 Performance-based restricted stock Number of Grant-Date Outstanding at beginning of year — $ — Expected to vest 123,851 $ 17.79 Vested — $ — Outstanding at June 30, 2019 123,851 $ 17.79 For the period ended June 30, 2019, $2.2 $283,000 $490,000 three six June 30, 2019, June 30, 2019, $1.7 1.5 Total Stock Compensation Expense We recorded total stock compensation expense for the three six June 30, 2019 2018, Three Month Period Ended Six Month Period Ended June 30, June 30, (In thousands) 2019 2018 2019 2018 Research and development costs $ 97 $ 65 $ 177 $ 130 Sales and marketing costs 131 69 297 138 General and administrative costs 350 191 677 382 Cost of product sales 68 49 101 98 Total $ 646 $ 374 $ 1,252 $ 748

Note 7 - Warrants

Note 7 - Warrants	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Warrants [Text Block]	7. Warrants At June 30, 2019 December 31, 2018, 4,048,505 4,080,005 $4.34 $4.35, three six June 30, 2019, 24,000 29,000 $4.75 $114,000 $138,000, March 2021 May 2021.

Note 8 - Income Taxes

Note 8 - Income Taxes	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	8. Income Taxes We have recorded a full valuation allowance against our deferred tax assets. As we continue to have multiple quarters of positive net income, we will assess our valuation allowance. Based on all available evidence, we determined that we have not June 30, 2019. may

Note 9 - Net Income (Loss) Per

Note 9 - Net Income (Loss) Per Common Share	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	9. Net Income (Loss) per Common Share Basic earnings per share is calculated by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated using the weighted average number of common shares outstanding plus dilutive common stock equivalents outstanding as determined by the treasury method during the period. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect. For the three six June 30, 2019 2018, The following table shows the calculation of basic and diluted earnings per shares: Three Month Period Ended Six Month Period Ended June 30, June 30, (In thousands, except per share and share data) 2019 2018 2019 2018 Numerator: Net income attributable to common stockholders $ 838 $ 1,046 $ 1,265 $ 943 Denominator: Weighted average basic shares outstanding 18,819,459 15,180,169 18,734,401 14,642,378 Effect of dilutive securities 5,719,840 5,194,189 5,705,558 4,421,217 Weighted average diluted shares 24,539,299 20,374,358 24,439,959 19,063,595 Basic earnings per share $ 0.04 $ 0.07 $ 0.07 $ 0.06 Diluted earnings per share $ 0.03 $ 0.05 $ 0.05 $ 0.05

Note 10 - Commitments & Conting

Note 10 - Commitments & Contingencies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Commitments & Contingencies Employment Agreements We have employment agreements with our Chief Executive Officer, Chief Financial Officer, Chief Technology Officer, Vice President of Operations, Vice President of Marketing, Vice President of Sales – Thaw Technologies, Vice President of Product Development – Thaw Technologies and Vice President of Sales. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none

Note 11 - Revenue

Note 11 - Revenue	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	11 . Revenue We currently operate as one The following table disaggregates revenue by market segment and distributors: Three Month Period Ended Six Month Period Ended June 30, June 30, (In thousands) 2019 2018 2019 2018 Net product sales: Regenerative medicine $ 3,978 $ 2,985 $ 6,157 $ 5,089 Distributors 2,215 1,695 5,319 2,734 Drug discovery 248 263 486 640 BioBanking 260 235 509 530 Total $ 6,701 $ 5,178 $ 12,471 $ 8,993 The following table disaggregates revenue by product category: Three Month Period Ended Six Month Period Ended June 30, June 30, (In thousands) 2019 2018 2019 2018 Net product sales: Media $ 6,327 $ 5,178 $ 12,097 $ 8,993 Automated thawing products 374 — 374 — Total $ 6,701 $ 5,178 $ 12,471 $ 8,993

Note 12 - Leases

Note 12 - Leases	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Lessee, Leases [Text Block]	12. Leases Our operating leases are primarily related to our Bothell, Washington headquarters space lease. The term of our lease continues until July 31, 2021 two five first August 1, 2021, second first not not 6.5%, 8.1%, 2.0 1.7 three June 30, 2019 $142,000 $186,000, six June 30, 2019 $285,000 $371,000, Maturities of lease liabilities as of June 30, 2019 (In thousands) Operating Leases Financing Leases 2019 (less than one year) $ 362 $ 7 2020 764 15 2021 452 3 Total lease payments 1,578 25 Less: interest (107 ) (2 ) Total present value of lease liabilities $ 1,471 $ 23

Note 13 - Subsequent Event

Note 13 - Subsequent Event	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	13. Subsequent Event On July 8, 2019, 56% not 1.1 August 7, 2019. Due to the limited time since the acquisition date and the effort required to assess the fair value of assets acquired and liabilities assumed, the initial accounting for the business combination is incomplete at the time of this filing. As a result, the Company is unable to provide the amounts recognized for the major classes of assets acquired and liabilities assumed, acquisition contingencies and goodwill. Also, the Company is unable to provide pro forma revenues and earnings of the combined entity. This information is expected to be included in the Company's Quarterly Report on Form 10 September 30, 2019.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation We have prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not may 10 December 31, 2018 Changes in Significant Accounting Policies The following significant accounting policies have been added or updated since our Annual Report on Form 10 December 31, 2018. Business Combinations The Company’s identifiable assets acquired and liabilities assumed in a business combination are recorded at their acquisition date fair values. The valuation requires management to make significant estimates and assumptions, especially with respect to long-lived and intangible assets. Critical estimates in valuing intangible assets include, but are not ● future expected cash flows, including revenue and expense projections; ● discount rates to determine the present value of recognized assets and liabilities and; ● revenue volatility to determine contingent consideration using option pricing models The Company’s estimates of fair value are based upon assumptions it believes to be reasonable, but that are inherently uncertain and unpredictable. Assumptions may may Goodwill is calculated as the excess of the purchase price over the fair value of net assets acquired, including the amount assigned to identifiable intangible assets. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which these costs are incurred. The results of operations of an acquired business are included in the consolidated financial statements beginning at the acquisition date. The Company estimates the acquisition date fair value of the acquisition-related contingent consideration using various valuation approaches, including option pricing models, as well as significant unobservable inputs, reflecting the Company’s assessment of the assumptions market participants would use to value these liabilities. The fair value of the contingent consideration is remeasured each reporting period, with any change in the value recorded as other income or expense. During the measurement period, which may one Goodwill Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. Goodwill is not fourth may first not 350. not 50 not not not not June 30, 2019, no Intangible Assets Intangible assets consist of developed technology, customer relationships, and tradenames and trademarks, resulting from the Company’s acquisitions. Intangible assets are recorded at fair value on the date of acquisition and amortized over their estimated useful lives on a straight-line basis. Significant Accounting Policies Update In February 2016, No. 2016 02, 842 2016 02” 2016 02. We adopted ASU 2016 02 842 January 1, 2019 not January 1, 2019 840, January 1, 2019. The adoption of this standard resulted in the recording of operating lease right-of-use assets of $1.3 $1.8 January 1, 2019. $0.5 842. 842 not no
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements for the three six June 30, 2019 April 1, 2019, April 1, 2019 three six June 30, 2018 December 31, 2018,
Equity Method Investments [Policy Text Block]	Equity Method Investments We account for our ownership in SAVSU Technologies, Inc. (“SAVSU”) using the equity method of accounting. This method states that if the investment provides us the ability to exercise significant influence, but not 20% 50%, three six June 30, 2019, $0.5 $1.0 $0.2 $0.4 three six June 30, 2018, $0.6 $1.1 $0.2 $0.3
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of credit risk and business risk In the three June 30, 2019, 17% one six June 30, 2019, 20% one three June 30, 2018, 38% three six June 30, 2018, 27% two No 10% three six June 30, 2019 2018. three June 30, 2019 2018, 82% 87%, six June 30, 2019 2018, 86%, June 30, 2019, two 28% December 31, 2018, three 71% Revenue from customers located in Canada represented 17% 20% 12% 14% three six June 30, 2019, 11% 12% 11% 11% three six June 30, 2018,
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements There have been no not

Note 2 - Fair Value Measureme_2

Note 2 - Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	As of June 30, 2019 Level 1 Level 2 Level 3 Total Assets: Total cash and cash equivalents $ 19,617 $ — $ — $ 19,617 Liabilities: Contingent consideration - business combinations $ — $ — $ 1,931 $ 1,931 As of December 31, 2018 Level 1 Level 2 Total Total cash and cash equivalents $ 30,657 $ — $ 30,657

Note 3 - Acquisition of Aster_2

Note 3 - Acquisition of Astero Bio Corporation (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Cash consideration $ 12,521 Contingent consideration 1,931 Working capital adjustment (71 ) Total consideration transferred $ 14,381
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Cash and cash equivalents $ 12 Accounts receivable 154 Inventory 456 Customer relationships 160 Tradenames 470 Developed technology 3,920 Goodwill 9,524 Other assets 100 Accounts Payable (251 ) Other liabilities (164 ) Fair value of net assets acquired $ 14,381 Estimated Fair Value Estimated Useful Life (Years) Customer relationships $ 160 4 Tradenames 470 9 Developed technologies 3,920 5 – 9 Total identifiable intangible assets $ 4,550
Business Acquisition, Pro Forma Information [Table Text Block]	Six Months Ended June 30, (In thousands) 2019 2018 Total revenue $ 12,681 $ 9,016 Net income attributable to common stockholders $ 801 $ 258 Earnings per share: Basic $ 0.04 $ 0.02 Diluted $ 0.03 $ 0.01

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(In thousands) June 30, 2019 December 31, 2018 Raw materials $ 2,068 $ 1,453 Work in progress 275 652 Finished goods 2,963 1,404 Total $ 5,306 $ 3,509

Note 5 - Deferred Rent (Tables)

Note 5 - Deferred Rent (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Deferred Rent [Table Text Block]	(In thousands) December 31, 2018 Landlord-funded leasehold improvements $ 1,125 Less accumulated amortization (757 ) Total 368 Straight line rent adjustment 111 Total deferred rent $ 479

Note 6 - Share-based Compensa_2

Note 6 - Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Six Month Period Ended June 30, 2019 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 2,043,402 $ 1.91 Granted — $ — Exercised (236,061 ) $ 1.96 Forfeited (3,438 ) $ 5.69 Expired — $ — Outstanding service vesting-based at June 30, 2019 1,803,903 $ 1.90 Service vesting-based options exercisable at June 30, 2019 1,600,799 $ 1.87 Six Month Period Ended June 30, 2019 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 964,997 $ 1.64 Granted — $ — Exercised — $ — Outstanding performance-based at June 30, 2019 964,997 $ 1.64 Performance-based options exercisable at June 30, 2019 964,997 $ 1.64
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Six Month Period Ended June 30, 2019 Service vesting-based restricted stock Number of Grant-Date Outstanding at beginning of year 279,919 $ 5.00 Granted 177,718 $ 17.80 Vested (86,142 ) $ 4.51 Forfeited (21,269 ) $ 10.17 Outstanding at June 30, 2019 350,226 $ 11.30 Six Month Period Ended June 30, 2019 Performance-based restricted stock Number of Grant-Date Outstanding at beginning of year — $ — Expected to vest 123,851 $ 17.79 Vested — $ — Outstanding at June 30, 2019 123,851 $ 17.79
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Month Period Ended Six Month Period Ended June 30, June 30, (In thousands) 2019 2018 2019 2018 Research and development costs $ 97 $ 65 $ 177 $ 130 Sales and marketing costs 131 69 297 138 General and administrative costs 350 191 677 382 Cost of product sales 68 49 101 98 Total $ 646 $ 374 $ 1,252 $ 748

Note 9 - Net Income (Loss) Pe_2

Note 9 - Net Income (Loss) Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Month Period Ended Six Month Period Ended June 30, June 30, (In thousands, except per share and share data) 2019 2018 2019 2018 Numerator: Net income attributable to common stockholders $ 838 $ 1,046 $ 1,265 $ 943 Denominator: Weighted average basic shares outstanding 18,819,459 15,180,169 18,734,401 14,642,378 Effect of dilutive securities 5,719,840 5,194,189 5,705,558 4,421,217 Weighted average diluted shares 24,539,299 20,374,358 24,439,959 19,063,595 Basic earnings per share $ 0.04 $ 0.07 $ 0.07 $ 0.06 Diluted earnings per share $ 0.03 $ 0.05 $ 0.05 $ 0.05

Note 11 - Revenue (Tables)

Note 11 - Revenue (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Month Period Ended Six Month Period Ended June 30, June 30, (In thousands) 2019 2018 2019 2018 Net product sales: Regenerative medicine $ 3,978 $ 2,985 $ 6,157 $ 5,089 Distributors 2,215 1,695 5,319 2,734 Drug discovery 248 263 486 640 BioBanking 260 235 509 530 Total $ 6,701 $ 5,178 $ 12,471 $ 8,993 Three Month Period Ended Six Month Period Ended June 30, June 30, (In thousands) 2019 2018 2019 2018 Net product sales: Media $ 6,327 $ 5,178 $ 12,097 $ 8,993 Automated thawing products 374 — 374 — Total $ 6,701 $ 5,178 $ 12,471 $ 8,993

Note 12 - Leases (Tables)

Note 12 - Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	(In thousands) Operating Leases Financing Leases 2019 (less than one year) $ 362 $ 7 2020 764 15 2021 452 3 Total lease payments 1,578 25 Less: interest (107 ) (2 ) Total present value of lease liabilities $ 1,471 $ 23

Note 1 - Organization and Sig_2

Note 1 - Organization and Significant Accounting Policies (Details Textual) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Jan. 01, 2019USD ($)
Operating Lease, Right-of-Use Asset	$ 1,079		$ 1,079			$ 1,300
Operating Lease, Liability, Total	1,471		1,471			$ 1,800
Deferred Rent Credit					$ 479
Net Income (Loss) Attributable to Parent, Total	838	$ 1,139	1,265	$ 1,143
Income (Loss) from Equity Method Investments, Total	$ (217)	$ (177)	$ (448)	$ (321)
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Percentage	17.00%	38.00%	20.00%	27.00%
Number of Major Customers	1	3	1	2
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | CANADA
Concentration Risk, Percentage	17.00%	11.00%	20.00%	12.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Non-US [Member]
Concentration Risk, Percentage	12.00%	11.00%	14.00%	11.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | CryoStor Products [Member]
Concentration Risk, Percentage	82.00%	87.00%	86.00%	86.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage			28.00%		71.00%
Number of Major Customers			2		3
SAVSU [Member]
Income (Loss) from Equity Method Investments, Total	$ (200)	$ (200)	$ (400)	$ (300)
SAVSU [Member]
Net Income (Loss) Attributable to Parent, Total	$ (500)	$ (600)	$ (1,000)	$ (1,100)

Note 2 - Fair Value Measureme_3

Note 2 - Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 0	$ 0
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure	$ 0	$ 0

Note 2 - Fair Value Measureme_4

Note 2 - Fair Value Measurement - Financial Assets on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Contingent consideration - business combinations	$ 0	$ 0
Fair Value, Inputs, Level 2 [Member]
Total cash and cash equivalents	0	0
Fair Value, Inputs, Level 3 [Member]
Total cash and cash equivalents	0	0
Fair Value, Recurring [Member]
Total cash and cash equivalents	19,617	30,657
Contingent consideration - business combinations	1,931
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Total cash and cash equivalents	19,617	30,657
Contingent consideration - business combinations
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Total cash and cash equivalents
Contingent consideration - business combinations
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Total cash and cash equivalents
Contingent consideration - business combinations	$ 1,931

Note 3 - Acquisition of Aster_3

Note 3 - Acquisition of Astero Bio Corporation (Details Textual) - USD ($)	Apr. 01, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Goodwill, Ending Balance		$ 9,524,000		$ 9,524,000
Business Combination, Acquisition Related Costs		39,000		247,000
Astero [Member]
Payments to Acquire Businesses, Gross	$ 12,521,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	8,500,000
Business Combination, Contingent Consideration, Liability, Total	1,900,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Tangible Assets	324,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	4,600,000
Goodwill, Ending Balance	$ 9,500,000	9,524,000		9,524,000
Business Combination, Acquisition Related Costs		39,000		247,000	103,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual		374,000		374,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual		$ (542,000)		(542,000)
Business Combination, Pro Forma Information, Amortization Expense				104,000	208,000
Business Combination, Pro Forma Information, Share-based Compensation Expense				108,000	216,000
Business Combination, Pro Forma Information, Employee Related Expense				$ 47,000	$ 94,000

Note 3 - Acquisition of Aster_4

Note 3 - Acquisition of Astero Bio Corporation - Consideration Transferred (Details) - Astero [Member] $ in Thousands	Apr. 01, 2019USD ($)
Cash consideration	$ 12,521
Contingent consideration	1,931
Working capital adjustment	(71)
Total consideration transferred	$ 14,381

Note 3 - Acquisition of Aster_5

Note 3 - Acquisition of Astero Bio Corporation - Fair Value of Net Assets Acquired (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Jun. 30, 2019	Apr. 01, 2019	Dec. 31, 2018
Goodwill, Ending Balance		$ 9,524,000
Astero [Member]
Cash and cash equivalents		12,000
Accounts receivable		154,000
Inventory		456,000
Goodwill, Ending Balance		9,524,000	$ 9,500,000
Other assets		100,000
Accounts Payable		(251,000)
Other liabilities		(164,000)
Fair value of net assets acquired		14,381,000
Identifiable intangible assets	$ 4,550,000
Astero [Member] | Customer Relationships [Member]
Intangible assets		160,000
Identifiable intangible assets	$ 160,000
Identifiable intangible assets useful life (Year)	4 years
Astero [Member] | Trade Names [Member]
Intangible assets		470,000
Identifiable intangible assets	$ 470,000
Identifiable intangible assets useful life (Year)	9 years
Astero [Member] | Developed Technology Rights [Member]
Intangible assets		$ 3,920,000
Identifiable intangible assets	$ 3,920,000
Astero [Member] | Developed Technology Rights [Member] | Minimum [Member]
Identifiable intangible assets useful life (Year)	5 years
Astero [Member] | Developed Technology Rights [Member] | Maximum [Member]
Identifiable intangible assets useful life (Year)	9 years

Note 3 - Acquisition of Aster_6

Note 3 - Acquisition of Astero Bio Corporation - Pro Forma Information (Details) - Astero [Member] - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Total revenue	$ 12,681	$ 9,016
Net income attributable to common stockholders	$ 801	$ 258
Basic (in dollars per share)	$ 0.04	$ 0.02
Diluted (in dollars per share)	$ 0.03	$ 0.01

Note 4 - Inventory - Summary of

Note 4 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Raw materials	$ 2,068	$ 1,453
Work in progress	275	652
Finished goods	2,963	1,404
Total	$ 5,306	$ 3,509

Note 5 - Deferred Rent (Details

Note 5 - Deferred Rent (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Amortization of Deferred Rent	$ 0	$ 32,000	$ 0	$ 63,000

Note 5 - Deferred Rent - Summar

Note 5 - Deferred Rent - Summary of Deferred Rent (Details) $ in Thousands	Dec. 31, 2018USD ($)
Landlord-funded leasehold improvements	$ 1,125
Less accumulated amortization	(757)
Total	368
Straight line rent adjustment	111
Total deferred rent	$ 479

Note 6 - Share-based Compensa_3

Note 6 - Share-based Compensation (Details Textual) - USD ($)	Apr. 01, 2019	Feb. 27, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2017
Share-based Payment Arrangement, Expense			$ 646,000	$ 374,000	$ 1,252,000	$ 748,000
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense			95,000	149,000	240,000	303,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value			27,200,000		27,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value			24,100,000		24,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value			2,000,000	724,000	$ 3,500,000	$ 1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term					5 years 73 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term					5 years 36 days
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			279,000		$ 279,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition					1 year 146 days
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member]
Share-based Payment Arrangement, Expense			0	127,000	$ 0	$ 252,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value			14,800,000		14,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value			14,800,000		14,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value			$ 0	$ 285,000	$ 0	$ 285,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			0	0	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term					2 years 182 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term					2 years 182 days
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price							$ 1.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number		999,997
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Vesting on Release of Audited Financial Statements for 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							50.00%
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Vesting One Year After Release of Audited Financial Statements for 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							50.00%
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%
Restricted Stock [Member]
Share-based Payment Arrangement, Expense			$ 268,000	$ 98,000	$ 522,000	$ 193,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			3,600,000		$ 3,600,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition					3 years 146 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value			548,000	154,000	$ 3,200,000	1,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value			369,000	$ 174,000	$ 1,200,000	$ 481,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					177,718
Performance-based Restricted Stock [Member]
Share-based Payment Arrangement, Expense			283,000		$ 490,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 1,700,000		$ 1,700,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition					1 year 182 days
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			94,247		94,247
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	29,604				123,851
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding			$ 2,200,000		$ 2,200,000
Performance-based Restricted Stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards					0.00%
Performance-based Restricted Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			188,494		188,494
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards					200.00%

Note 6 - Share-based Compensa_4

Note 6 - Share-based Compensation - Stock Option Activity (Details) - $ / shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019
Share-based Payment Arrangement, Option [Member]
Outstanding (in shares)	2,043,402
Outstanding at beginning of year, weighted average exercise price (in dollars per share)	$ 1.91
Granted (in shares)	0	0
Granted, weighted average exercise price (in dollars per share)
Exercised (in shares)	(236,061)
Exercised, weighted average exercise price (in dollars per share)	$ 1.96
Forfeited (in shares)	(3,438)
Forfeited, weighted average exercise price (in dollars per share)	$ 5.69
Expired (in shares)
Expired, weighted average exercise price (in dollars per share)
Outstanding (in shares)	1,803,903
Outstanding at end of year, weighted average exercise price (in dollars per share)	$ 1.90
Stock options exercisable at year end (in shares)	1,600,799		1,600,799
Stock options exercisable at year end, weighted average exercise price (in dollars per share)			$ 1.87
Outstanding (in shares)	1,600,799
Performance Shares [Member]
Outstanding at beginning of year, weighted average exercise price (in dollars per share)	$ 1.64
Granted (in shares)
Granted, weighted average exercise price (in dollars per share)
Exercised (in shares)
Exercised, weighted average exercise price (in dollars per share)
Outstanding at end of year, weighted average exercise price (in dollars per share)	$ 1.64
Stock options exercisable at year end (in shares)	964,997		964,997
Stock options exercisable at year end, weighted average exercise price (in dollars per share)			$ 1.64
Outstanding (in shares)	964,997
Outstanding (in shares)	964,997

Note 6 - Share-based Compensa_5

Note 6 - Share-based Compensation - Restricted Stock Activity (Details) - $ / shares	Apr. 01, 2019	Jun. 30, 2019
Restricted Stock [Member]
Outstanding at beginning of year (in shares)		279,919
Outstanding at beginning of year (in dollars per share)		$ 5
Unvested granted (in shares)		177,718
Granted, grant date fair value (in dollars per share)		$ 17.80
Vested (in shares)		(86,142)
Vested, grant date fair value (in dollars per share)		$ 4.51
Forfeited (in shares)		(21,269)
Forfeited, grant date fair value (in dollars per share)		$ 10.17
Outstanding (in shares)		350,226
Outstanding (in dollars per share)		$ 11.30
Performance-based Restricted Stock [Member]
Outstanding at beginning of year (in shares)
Outstanding at beginning of year (in dollars per share)
Unvested granted (in shares)	29,604	123,851
Granted, grant date fair value (in dollars per share)		$ 17.79
Vested (in shares)
Vested, grant date fair value (in dollars per share)
Outstanding (in shares)		123,851
Outstanding (in dollars per share)		$ 17.79

Note 6 - Share-based Compensa_6

Note 6 - Share-based Compensation - Stock Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Stock compensation expense	$ 646	$ 374	$ 1,252	$ 748
Research and Development Expense [Member]
Stock compensation expense	97	65	177	130
Selling and Marketing Expense [Member]
Stock compensation expense	131	69	297	138
General and Administrative Expense [Member]
Stock compensation expense	350	191	677	382
Cost of Sales [Member]
Stock compensation expense	$ 68	$ 49	$ 101	$ 98

Note 7 - Warrants (Details Text

Note 7 - Warrants (Details Textual) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Class of Warrant or Right, Outstanding	4,048,505	4,048,505	4,080,005
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.34	$ 4.34	$ 4.35
Class of Warrant or Right, Exercised During Period	24,000	29,000
Class of Warrant or Right, Exercised During Period, Exercise Price	$ 4.75	$ 4.75
Proceeds from Warrant Exercises	$ 114,000	$ 138,000

Note 9 - Net Income (Loss) Pe_3

Note 9 - Net Income (Loss) Per Common Share - Calculation of Diluted Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net income attributable to common stockholders	$ 838	$ 1,046	$ 1,265	$ 943
Basic shares used to compute earnings per share (in shares)	18,819,459	15,180,169	18,734,401	14,642,378
Effect of dilutive securities (in shares)	5,719,840	5,194,189	5,705,558	4,421,217
Weighted average diluted shares (in shares)	24,539,299	20,374,358	24,439,959	19,063,595
Basic net income per common share (in dollars per share)	$ 0.04	$ 0.07	$ 0.07	$ 0.06
Diluted net income per common share (in dollars per share)	$ 0.03	$ 0.05	$ 0.05	$ 0.05

Note 11 - Revenue - Disaggregat

Note 11 - Revenue - Disaggregated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net product sales	$ 6,701	$ 5,178	$ 12,471	$ 8,993
Regenerative Medicine [Member]
Net product sales	3,978	2,985	6,157	5,089
Media [Member]
Net product sales	6,327	5,178	12,097	8,993
Distribution Service [Member]
Net product sales	2,215	1,695	5,319	2,734
Automated Thawing Products [Member]
Net product sales	374		374
Drug Discovery [Member]
Net product sales	248	263	486	640
BioBanking [Member]
Net product sales	$ 260	$ 235	$ 509	$ 530

Note 12 - Leases (Details Textu

Note 12 - Leases (Details Textual)	3 Months Ended	6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2019USD ($)
Operating Lease, Weighted Average Discount Rate, Percent	6.50%	6.50%
Finance Lease, Weighted Average Discount Rate, Percent	8.10%	8.10%
Operating Lease, Weighted Average Remaining Lease Term	2 years	2 years
Finance Lease, Weighted Average Remaining Lease Term	1 year 255 days	1 year 255 days
Operating Lease, Cost	$ 142,000	$ 285,000
Operating Lease, Payments	$ 186,000	$ 371,000
Bothell, Washington Headquarters [Member]
Lessee, Operating Lease, Renewal Term	5 years	5 years

Note 12 - Leases - Maturities o

Note 12 - Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019
2019, operating leases	$ 362
2019, financing leases	7
2020, operating leases	764
2020, financing leases	15
2021, operating leases	452
2021, financing leases	3
Total operating lease payments	1,578
Total financing lease payments	25
Less: operating lease interest	(107)
Less: financing lease interest	(2)
Total present value of operating lease liabilities	1,471	$ 1,800
Total present value of financing lease liabilities	$ 23

Note 13 - Subsequent Event (Det

Note 13 - Subsequent Event (Details Textual) - SAVSU [Member] - Subsequent Event [Member] shares in Millions	1 Months Ended
	Aug. 08, 2019shares
Business Acquisition, Percentage of Voting Interests Acquired	56.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	1.1